Wells Fargo & Company Geo Vax Labs, Inc. Transaction History

Wells Fargo & Company

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.3 - $0.57 $108 - $206	-363 Reduced 7.95%	4,205 $1,000
Q3 2023 Nov 13, 2023	SELL	$0.51 - $0.62 $62 - $75	-122 Reduced 2.6%	4,568 $2,000
Q2 2023 Aug 15, 2023	BUY	$0.55 - $0.75 $70 - $96	128 Added 2.81%	4,690 $2,000
Q1 2023 May 12, 2023	BUY	$0.62 - $1.11 $621 - $1,113	1,003 Added 28.18%	4,562 $3,000
Q4 2022 Feb 13, 2023	BUY	$0.55 - $17.1 $8 - $256	15 Added 0.42%	3,559 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.4 - $58.5 $592 - $86,638	1,481 Added 71.79%	3,544 $4,000
Q2 2022 Aug 12, 2022	BUY	$9.29 - $34.8 $176 - $661	19 Added 0.93%	2,063 $2,000
Q1 2022 May 16, 2022	BUY	$17.25 - $58.95 $86 - $294	5 Added 0.25%	2,044 $2,000
Q4 2021 Feb 14, 2022	SELL	$52.65 - $71.7 $44,752 - $60,945	-850 Reduced 29.42%	2,039 $7,000
Q3 2021 Nov 15, 2021	SELL	$56.4 - $91.35 $8,572 - $13,885	-152 Reduced 5.0%	2,889 $12,000
Q2 2021 Aug 16, 2021	SELL	$64.8 - $94.5 $485,805 - $708,466	-7,497 Reduced 71.14%	3,041 $15,000
Q1 2021 May 13, 2021	BUY	$49.05 - $126.6 $515,662 - $1.33 Million	10,513 Added 42052.0%	10,538 $46,000
Q4 2020 Feb 09, 2021	BUY	$39.45 - $85.95 $986 - $2,148	25 New	25 $0

Ticker GOVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,744,000
Market Cap $55.9M
Description
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhag...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.